---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-033990"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:21:01.241873+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma reports Q4/FY2023 net loss $8.7M; cash runway to H2 2025; positive QRX003 data

## Summary
- Net loss Q4 2023 $2.0M (flat YoY); FY2023 $8.7M vs $9.4M in 2022.
- Cash & equivalents $10.7M as of Dec 31, 2023; plus $6.5M March 5 offering and $8M ELOC (pending shareholder approval).
- Positive initial data from first 6 evaluable subjects: 5/6 had negligible/absent itch; all 6 showed skin score improvement.
- No safety concerns reported in either ongoing Netherton Syndrome study; enrollment age lowered to 14+.
- Expects cash runway to extend into H2 2025.

## SEC filing metadata
- accession: 0001104659-24-033990
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465924033990/0001104659-24-033990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465924033990/tm248782d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-033990
- JSON: https://secwatch.observer/filing/0001104659-24-033990.json
- Plain text: https://secwatch.observer/filing/0001104659-24-033990.txt

## Key facts
- Earnings Releases
  Quoin Pharmaceuticals, Ltd. reported the quarter and year ended December 31, 2023 results: net income Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f.
  - Period: the quarter and year ended December 31, 2023
  - Net income: Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f
  - Result: reported results
  source text: Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465924033990/0001104659-24-033990-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.